FOLH1 and prostate carcinoma: PSMA radioligand therapy has emerged as a significant therapeutic in prostate cancer (28), where small-molecule PSMA inhibitors are labeled with both beta- and alpha-emitting radioisotopes, with different energy levels and path lengths.